HomeAI · summaries
Storia in 3 fonti
Ultragenyx to weigh ‘significant’ cost cuts as Angelman drug fails key study
The failure of what was once considered a potential blockbuster therapy represents a major setback in a tough-to-treat disease and is forcing Ultragenyx to closely examine its expenses.
Confronto fonti
3 prospettive sulla stessa storiaTimeline cronologica
- ·
biopharmadive.com
Ultragenyx to weigh ‘significant’ cost cuts as Angelman drug fails key study
The failure of what was once considered a potential blockbuster therapy represents a major setback in a tough-to-treat disease and is forcing Ultragenyx to closely examine its…
- ·
endpoints.news
Ultragenyx’s Angelman therapy fails Phase 3 trial in setback for company and patients
Ultragenyx's Phase 3 Aspire trial of apazunersen misses its primary and key secondary endpoints in Angelman syndrome, sending shares down more than 40%.
